![Mads Buhl Axelsen](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Mads Buhl Axelsen
Direttore Tecnico/Scientifico/R&S presso GUBRA A/S
Posizioni attive di Mads Buhl Axelsen
Società | Posizione | Inizio | Fine |
---|---|---|---|
GUBRA A/S | Direttore Tecnico/Scientifico/R&S | 01/08/2022 | - |
Storia della carriera di Mads Buhl Axelsen
Precedenti posizioni note di Mads Buhl Axelsen
Società | Posizione | Inizio | Fine |
---|---|---|---|
Neurokey A/S
![]() Neurokey A/S Pharmaceuticals: MajorHealth Technology Neurokey wants to become a leading drug development company in the critical care field. The drugs under development will one day help countless patients suffering from the effects of debilitating and potentially fatal cardiovascular and neurological; diseases. Neurokey will be first to market with reliable efficient and easily administered medication that will increase the survival rate for these patients and dramatically minimize the risk of permanent neurological damage. | Direttore Tecnico/Scientifico/R&S | 15/04/2010 | 30/07/2010 |
Aros Pharma ApS
![]() Aros Pharma ApS Pharmaceuticals: MajorHealth Technology Aros Pharma ApS is a holding company that develops medicine targeting unmet needs within pain relief, infectious disease, inflammation, respiratory diseases, and immuno-suppressed patients. It is a biotech company that focuses on clinical development of a novel therapy for the treatment of gastrointestinal pain. The firm is developing a new pain relief therapy based on a small molecule (PPC-5650) that is a specific inhibitor of the ASIC 1a receptor (Acid Sensing Ion Channel subtype 1a). Its therapy is currently being tested in two phase I trials targeting pain in patients who suffer from Irritable Bowel Syndrome (IBS) or non-erosive Gastroesophageal Reflux Disease (NERD). The company was founded in 2009 and is headquartered in Copenhagen, Denmark. | Direttore/Membro del Consiglio | - | - |
Leo Co. Ltd. | Corporate Officer/Principal | - | - |
NOVO NORDISK A/S | Corporate Officer/Principal | - | - |
Azanta Danmark A/S
![]() Azanta Danmark A/S Pharmaceuticals: MajorHealth Technology Azanta Danmark A/S operates as biopharmaceutical company developing treatments for women's health indications and for orphan oncology. The firm develops protein therapeutics within oncology and infectious diseases. The company was founded by Martin N. Bonde, Jens Christian Jensenius, Steffen Thiel, and R. Alan B. Ezekowitz in 2000 and is headquartered in Valby, Denmark. | Direttore Tecnico/Scientifico/R&S | 01/03/2004 | - |
Formazione di Mads Buhl Axelsen
University of Copenhagen | Doctorate Degree |
Statistiche
Distribuzione geografica
Danimarca | 7 |
Giappone | 2 |
Posizioni
Chief Tech/Sci/R&D Officer | 3 |
Corporate Officer/Principal | 2 |
Doctorate Degree | 1 |
Settori
Health Technology | 5 |
Consumer Services | 2 |
Retail Trade | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 2 |
---|---|
NOVO NORDISK A/S | Health Technology |
GUBRA A/S | Commercial Services |
Aziende private | 4 |
---|---|
Azanta Danmark A/S
![]() Azanta Danmark A/S Pharmaceuticals: MajorHealth Technology Azanta Danmark A/S operates as biopharmaceutical company developing treatments for women's health indications and for orphan oncology. The firm develops protein therapeutics within oncology and infectious diseases. The company was founded by Martin N. Bonde, Jens Christian Jensenius, Steffen Thiel, and R. Alan B. Ezekowitz in 2000 and is headquartered in Valby, Denmark. | Health Technology |
Leo Co. Ltd. | Retail Trade |
Neurokey A/S
![]() Neurokey A/S Pharmaceuticals: MajorHealth Technology Neurokey wants to become a leading drug development company in the critical care field. The drugs under development will one day help countless patients suffering from the effects of debilitating and potentially fatal cardiovascular and neurological; diseases. Neurokey will be first to market with reliable efficient and easily administered medication that will increase the survival rate for these patients and dramatically minimize the risk of permanent neurological damage. | Health Technology |
Aros Pharma ApS
![]() Aros Pharma ApS Pharmaceuticals: MajorHealth Technology Aros Pharma ApS is a holding company that develops medicine targeting unmet needs within pain relief, infectious disease, inflammation, respiratory diseases, and immuno-suppressed patients. It is a biotech company that focuses on clinical development of a novel therapy for the treatment of gastrointestinal pain. The firm is developing a new pain relief therapy based on a small molecule (PPC-5650) that is a specific inhibitor of the ASIC 1a receptor (Acid Sensing Ion Channel subtype 1a). Its therapy is currently being tested in two phase I trials targeting pain in patients who suffer from Irritable Bowel Syndrome (IBS) or non-erosive Gastroesophageal Reflux Disease (NERD). The company was founded in 2009 and is headquartered in Copenhagen, Denmark. | Health Technology |
- Borsa valori
- Insiders
- Mads Buhl Axelsen
- Esperienza